Pre-erythrocytic Activity of M5717 in Monotherapy and Combination in Preclinical Plasmodium Infection Models

[Image: see text] Combination therapies have emerged to mitigate Plasmodium drug resistance, which has hampered the fight against malaria. M5717 is a potent multistage antiplasmodial drug under clinical development, which inhibits parasite protein synthesis. The combination of M5717 with pyronaridin...

Descripción completa

Detalles Bibliográficos
Autores principales: Fontinha, Diana, Arez, Francisca, Gal, Isabella Ramella, Nogueira, Gonçalo, Moita, Diana, Baeurle, Tobias Hyun Ho, Brito, Catarina, Spangenberg, Thomas, Alves, Paula M., Prudêncio, Miguel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9003234/
https://www.ncbi.nlm.nih.gov/pubmed/35312290
http://dx.doi.org/10.1021/acsinfecdis.1c00640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9003234/
https://www.ncbi.nlm.nih.gov/pubmed/35312290
http://dx.doi.org/10.1021/acsinfecdis.1c00640

Ejemplares similares